VFA
KURA icon

Virtus Fund Advisers’s Kura Oncology KURA Stock Holding History

Virtus Fund Advisers’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$392K Buy
+25,648
New +$378K ﹤0.01% 360

Other funds holding KURA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Virtus Fund Advisers's KURA Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Kura Oncology (KURA) in Q4 2017: 25,648 shares worth $392K. The stake represents ﹤0.01% of the portfolio and ranks #360 among its holdings.

76 funds tracked by Wall St. Rank hold KURA as of Q4 2017.

  • Virtus Fund Advisers held 25,648 shares of Kura Oncology worth $392K as of Q4 2017.
  • Kura Oncology was a new Virtus Fund Advisers position in Q4 2017.
  • Kura Oncology made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #360 holding.
  • 76 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.